Radio and PodcastLive Radio & PodcastsLoading episode
Fetching episode details...
Radio and PodcastLive Radio & PodcastsRadio and PodcastLive Radio & PodcastsFetching episode details...
Radio and PodcastLive Radio & PodcastsKaryopharm is an oncology company that is commercializing XPOVIO (Selinexor) in Multiple Myeloma and DLBCL. Selinexor blocks nuclear export thereby hindering the ability of cancer cells to block tumor suppressor protein...
109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results is an episode from Breaking Biotech by Matthew Lepoire. Karyopharm is an oncology company that is commercializing XPOVIO (Selinexor) in Multiple Myel...
This episode belongs to Breaking Biotech.
Use the player on this page to stream the episode online.
Published Feb 22, 2022, 00:33:42 long, audio available.
Continue listening to more episodes from Breaking Biotech.
Apr 21, 2022 - 00:43:59
Apr 1, 2022 - 00:28:19
Feb 7, 2022 - 00:37:28
Jan 9, 2022 - 00:42:53